Milestone Pharmaceuticals To Present At Upcoming Investor Conferences
| Conference Details | |
| Wells Fargo 21 st Annual Healthcare Conference | |
| Format: | Fireside chat and 1x1s |
| Presentation Date: | September 8, 2026 |
| Time: | 1:30 pm ET |
| Location: | Boston, MA |
| Webcast link: | HERE |
| Cantor Global Healthcare Conference, New York | |
| Format: | 1x1s |
| Participation Date: | September 10, 2026 |
| Location: | New York, NY |
| H.C. Wainwright 28th Annual Global Investment Conference | |
| Format: | Fireside chat and 1x1s |
| Presentation Date: | September 15, 2026 |
| Time: | 10:30 am ET |
| Location: | New York, NY |
| Webcast link: | HERE |
To request a 1x1 meeting, please contact your representative at the relevant bank.
Webcasts of the presentations will be available for approximately 90 days following each event on the“News & Events” section of Milestone's website
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone's lead product is CARDAMYST® (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in Phase 3 development for the control of symptomatic episodic attacks associated with AFib-RVR.
Contact:
Investor Relations
Kevin Gardner, ...
Media Relations
Rebecca Novak, ...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment